Searched for
DRL RECALL
DRL, Zydus recall drugs in US over manufacturing issues: USFDADr Reddy's Laboratories and Zydus Lifesciences are recalling products in the US due to manufacturing issues. Dr Reddy's is recalling muscle...- Torrent, Zydus, EQT set to make the cut for $3 bn JB Chemicals buyoutTorrent Pharma and Zydus Lifesciences are vying to acquire JB Chemicals and Pharmaceuticals, with both firms shortlisted by KKR, the curren...
- Why Torrent Pharma is ready to go ahead with the daunting Cipla dealAhmedabad-based Torrent Pharma is seeking financing for a deal with Indian pharmaceutical company Cipla. Torrent Pharma is interested in bu...
- Stocks in the news: IDFC First Bank, IRB Infra, L&T, DRL & UltraTech CementIDFC First Bank said it has fixed the floor price at Rs 60.34 for the Rs 3,000 crore qualified institutional placement (QIP) issue.
- Stocks in the news: MTAR Tech, Vodafone Idea, Sun Pharma, BoB and MCXThe Niti Aayog has kept PSBs that were part of the last round of consolidation and State Bank India out of the privatisation plan.
- Dr Reddy's, Aurobindo recall drugs from US marketAccording to FDA, "Class-III" classification which was described as "a situation in which use of or exposure to a violative product is not ...
- Pharma will outperform in next 2-3 years: Deepak Shenoy, Capital MindFor next six months, I do not see a huge amount of positives for the pharma sector though.
- Dr Reddy's recalls Rivastigmine Tartrate capsules of 1.5 mg strength from USDr Reddy's Laboratories (DRL) has initiated voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market.
- Dr Reddy's Laboratories recalls anti-seizure, hypertension drugs from US marketThe firm has started recalling Divalproex Sodium extended-release tablets as it has failed dissolution tests.
- Sensex rangebound, Nifty off lows; top ten stocks in focusSensex managed to recoup losses after falling as much as 63 points in trade on Tuesday, led by gains in TCS, ICICI Bank, Infosys, Sun Pharm...
- Dr Reddy's recalls anti-gas drug from US marketThe drug was supplied to three different parties without label to enable them to sell the drug under their own label.
- Sensex tanks 300 points; twelve stocks in action“The Nifty is expected to head higher till 5640. In this period the key support will be at around 5550,” says Somil Mehta of Sharekhan.
- Dr Reddy's Laboratories recalls muscle relaxant drug from US marketDr Reddy's Laboratories has initiated recall of its tizanidine tablets, used as a muscle relaxant, from the US market due to labelling issu...
- Pharma companies look to be in better shape in March quarterGrowth in the domestic pharma sector, which has recovered marginally from the December quarter, still remains disappointing.
- Dr Reddy's to contest Pfizer's patent suit over atorvastatinDrug maker Dr Reddy's Laboratories will contest the patent infringement case filed against it by the global pharmaceutical giant Pfizer ove...
- Dr Reddy's nets Rs 167 crore in Q4Dr Reddy’s Laboratories bounced back into profit for the three months ended March, helped by the absence of any further provisioning for lo...
- Non-regulated markets, leverage to pep up growthAt Rs 860 crore, the one-time write-off of goodwill of Dr Reddy's Laboratories' German subsidiary, Betapharm, has severely impacted its con...
- Non-regulated markets, leverage to pep up growth of Dr Reddy's LabHad it not been for an extraordinary write-off, drug maker Dr Reddy’s Laboratories’ (DRL) December quarter results would have beaten market...
- Growth in US, local market to pep up DRLDr Reddy’s Laboratories (DRL), India’s third-largest pharma company, has seen a sharp rise of 25% in its stock price over the past fifteen ...
- How Dr Reddy's chased diabetes molecule dreamDr Reddy’s pursuit of past 13 years for the type 2 diabetes molecule is in its last lap, with the product entering the final phase of clini...
Load More
